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The critical role of IL-17 has recently been reported in a variety of conditions. Since IL-17 deeply participates in
the pathogenesis of psoriasis and keratinocyte production of certain cytokines, the involvement of T helper cell
17 (Th17) in atopic dermatitis (AD) is an issue to be elucidated. To evaluate the participation of Th17 cells in AD,
we successfully detected circulating lymphocytes intracellularly positive for IL-17 by flow cytometry, and the
IL-17þ cell population was found exclusively in CD3þCD4þ T cells. The percentage of Th17 cells was increased
in peripheral blood of AD patients and associated with severity of AD. There was a significant correlation
between the percentages of IL-17þ and IFN-gþ cells, although percentage of Th17 cells was not closely related
to Th1/Th2 balance. Immunohistochemically, IL-17þ cells infiltrated in the papillary dermis of atopic eczema
more markedly in the acute than chronic lesions. Finally, IL-17 stimulated keratinocytes to produce GM-CSF,
TNF-a, IL-8, CXCL10, and VEGF. A marked synergistic effect between IL-17 and IL-22 was observed on IL-8
production. The number of Th17 cells is increased in the peripheral blood and acute lesional skin of AD. Th17
cells may exaggerate atopic eczema.
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INTRODUCTION
IL-17-producing CD4þ T helper cells (Th17 cells) have
crucial functions in host defense, and dysregulated Th17 cell
responses mediate a variety of autoimmune and inflammatory
conditions such as rheumatoid arthritis, inflammatory bowel
disease, and experimental autoimmune encephalomyelitis
(McKenzie et al., 2006). IL-6 and transforming growth factor-
b are both required for induction of Th17 cells, whereas IL-23
is necessary for establishment of the Th17 lineage (Bettelli
et al., 2006; Mangan et al., 2006). Th17 cells coexpress IL-22
(Liang et al., 2006; Zheng et al., 2007), which belongs to the
IL-10 family of cytokines and its receptor is expressed
on a variety of epithelial tissues (Wolk et al., 2004). IL-17
and IL-22 cooperatively enhance some immunological
responses (Liang et al., 2006).
An important function of IL-17 is to coordinate local tissue
inflammation through upregulation of proinflammatory and
neutrophil-mobilizing cytokines and chemokines, including
IL-6, GM-CSF, tumor-necrosis factor-a (TNF-a), IL-1b, KC/
CXCL1, MCP-1/CCL2, MIP-2/CXCL2, MCP-3/CCL7, and MIP-
3a/CCL20, as well as matrix metalloproteases, to enable
activated T cells to migrate through the extracellular matrix
(Nakae et al., 2002; Kolls, 2006). A close relationship
between IL-17 and the cutaneous milieu has been suggested
by a number of observations. IL-17 induces production of
certain cytokines, chemokines, and antimicrobial peptides by
keratinocytes (Albanesi et al., 1999, 2000; Liang et al., 2006).
Its cooperation with IL-22 has been documented in the
antimicrobial peptide elaboration (Liang et al., 2006).
Recent findings have suggested that Th17 cells profoundly
participate in the pathogenesis of certain skin disorders, in
particular, psoriasis (Albanesi et al., 2000; Zheng et al., 2007).
In this Th1-mediated (Lew et al., 2004), chronic inflammatory
disease with epidermal hyperplasia, the role of IL-22 for
dermal inflammation and acanthosis is stressed (Boniface
et al., 2005; Zheng et al., 2007). On the other hand,
involvement of IL-17 has also been shown in allergen-specific
immune responses (Nakae et al., 2002; Kolls, 2006). IL-17
mRNA has been detected in skin affected by allergic contact
dermatitis (Teunissen et al., 1998) as well as psoriasis (Zheng
et al., 2007). Considering the proinflammatory property of
IL-17, it is an interesting issue whether and how Th17 cells
are involved in the pathogenesis of atopic dermatitis (AD), a
representative skin disease with a chronic clinical course
(Homey et al., 2006; Maintz and Novak, 2007). AD merits
Th17 investigation because it is known as a Th2 cell-mediated
disease, and one can evaluate the biased relationship between
Th17 cells and Th1/Th2 balance in relation to psoriasis.
Perhaps more importantly, the effects of IL-17 and resultant
outcomes on keratinocytes and dermal vasculature may
provide some insights to AD pathophysiology.
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In this study, we investigated Th17 cells in the peripheral
blood and skin lesions of AD, with a study of the effect of
IL-17 on the production of cytokines/chemokines and
vascular endothelial growth factor (VEGF) by keratinocytes.
In particular, to enumerate Th17 cell, we successfully
analyzed the cells by intracellular cytokine staining. Results
suggest that Th17 cells are elevated in the blood and can
function as an upmodulator in skin lesions of AD.
RESULTS
Increased percentage of IL-17þCD4þ T cells in PBMCs
from severe AD patients
The atopic patients enrolled in this study were divided into
three different severity groups (mild, moderate, and severe)
according to the criteria of Rajka and Langeland (1989). The
grouping was validated with a blood severity marker for AD,
lactate dehydrogenase (Mukai et al., 1990; Jacyk and
Ungerer, 1991; Figure 1). As reported previously (Mukai
et al., 1990), severity of AD correlates well with lactate
dehydrogenase level (Figure 1).
Circulating T cells bearing IL-17 in the cytoplasm were
examined in AD patients. Since CD4 expression on T cells is
downregulated during culture with the stimulants, CD3þ and
CD8þ T cells positive for intracytoplasmic IL-17 were
analyzed by flow cytometry. Figure 2 shows representative
flow cytometry data from an AD patient. There was a
discernible population of IL-17þCD3þ and IL-17þCD8
T cells in the peripheral blood mononuclear cells (PBMCs),
whereas the number of IL-17þCD8þ T cells was not
substantial, indicating that CD4þ T cells are the major
source of IL-17.
Figure 3a summarizes the percentages of IL-17þCD4þ
cells in the patients tested. The values differed significantly
among the three groups of AD patients, with different
severity. IL-17þCD4þ T-cell number was higher in the
severe group (0.71þ0.09) than the healthy control
(0.42þ0.07). The mean percentage of IL-17þCD4þ cells
in psoriasis vulgaris (1.3þ0.2) was slightly higher than that of
severe AD but there was no statistical significance. As for
expression of other cytokines, there was a tendency of both
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Figure 1. Lactate dehydrogenase levels in different severity groups of AD
patients. The AD patients were classified as acute (n¼ 23), mild (n¼7),
moderate (n¼5), and severe (n¼ 11) by clinical findings, and serum levels of
lactate dehydrogenase from AD patients were compared with that in healthy
donors. Student’s t-test was performed between the indicated groups and an
asterisk indicates Po 0.05.
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Figure 2. Flow cytometric analysis of IL-17þ cells in peripheral blood
lymphocytes. PBMCs isolated from a 30-year-old man with AD were
stimulated with PMA and ionomycin for 8 hours and Golgistop was added.
Then, production of IL-17 by PBMCs was determined at the single-cell level
by intracellular cytokine staining and flow cytometric analysis. The numbers
in the upper and lower right quadrants represent the percentage of IL-17þ
cells with or without expression of CD3þ or CD8þ cells in the total
lymphocyte populations gated.
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IFN-gþ T cells (11.4þ1.4) and IL-4þCD4þ cells
(0.49þ0.07) to be elevated in AD patients compared with
in healthy subjects (IFN-g, 9.2þ1.5; IL-4, 0.35þ0.07). IFN-
gþ T cells were also elevated markedly in psoriasis
(41.7þ10.6). In AD patients, a significant correlation
(R¼0.67, P¼0.0037) between the percentage of IL-
17þCD4þ cells and IFN-gþ T cells was found (Figure 3b),
but not between IL-17þCD4þ cells and IL-4þCD4þ cells
(data not shown). We also examined whether IL-17þCD4þ T
cells are related to Th1/Th2 balance. No significant correla-
tion was found between the number of IL-17þCD4þ T cells
and the ratio of IFN-gþ T cells/IL-4þCD4þ cells. These data
suggest that AD patients have a high percentage of Th17 cells
depending on the severity of atopic eczema, and the level of
Th17 cells is not closely associated with Th balance.
Infiltration of IL-17þ T cells in skin lesions of AD
Skin biopsy specimens were taken from acute and chronic
skin lesions of patients with mild, moderate, and severe AD.
The chronic form was defined by the presence of lichenified
or pruriginous eruptions, whereas scaly erythematous lesions
were categorized as the acute form. They were subjected to
immunohistochemical staining for IL-17, IFN-g, and IL-4.
IL-17-positive lymphocytes were found in the papillary areas
in the upper dermis, and some epidermotropic lymphocytes
also bore IL-17 (Figure 4a). The percentage of IL-17-bearing
lymphocytes was higher in the acute than in chronic lesions.
In acute lesions, the number of IL-17þ lymphocytes per high-
power field (HPF) depended on the severity of AD (Figure 4b).
There was no significant difference in the number of IFN-gþ
cells/HPF between the acute and chronic lesions, and IFN-gþ
cells/HPF tended to infiltrate at a higher percentage in the
severe form (1.18þ0.20) than in the mild form (0.70þ0.01).
As to IL-4þ cells/HPF, no significant difference existed
between acute and chronic lesions, but again, severity
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Figure 4. Immunohistochemistry of IL-17þ cells in skin lesions of AD.
(a) A skin specimen from an AD patient was immunohistochemically stained
for IL-17. Left, low-magnification image of acute lesion; top right,
high-magnification image of acute lesion; and bottom right, high-
magnification image of chronic lesion. Bar¼ 30 mm. (b) The number of
IL-17þ cells was enumerated in acute and chronic lesions from mild,
moderate, and severe cases of AD. Columns show mean±SD. Student’s t-test
was performed between the indicated groups and an the asterisk indicates
Po0.05.
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Figure 3. Percentage of circulating IL-17þ T cells in relation to AD severity
and IFN-cþ T cells. AD patients were divided into three different severity
groups (mild, n¼ 7; moderate, n¼ 5; and severe, n¼ 11). (a) Healthy subjects
(n¼9), three groups of AD, psoriatic patients (n¼ 16) were compared for
percentage of IL-17þ and CD4þ or CD8þ T cells, and a significant
correlation between healthy donors and severe AD patients was found
(P¼0.03). (b) IFN-gþ T cells of all AD patients were also analyzed.
A significant correlation between percentage of IL-17þ CD4þ T cells and
IFN-gþ T cells was found (P¼ 0.0009). In addition, the correlation (P-value)
between the percentage of IL-17þ CD4þ T cells and IFN-gþ T cells among
acute, moderate, and severe AD patients was depicted.
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dependency was observed in acute lesions (severe,
0.99þ0.20; mild, 0.68þ0.16).
Augmentation of keratinocyte production of GM-CSF, TNF-a,
IL-8, and VEGF by IL-17
The effect of IL-17 on keratinocyte production of GM-CSF,
TNF-a, IL-8, CCL5, CXCL10, CCL22, and VEGF was
examined in normal human epidermal keratinocytes
(NHEKs). GM-CSF and TNF-a are proinflammatory cytokines
and induce maturation of Langerhans cell and dermal
dendritic cells (Bechetoille et al., 2006). IL-8/CXCL8 attracts
neutrophils (Keller et al., 2005). VEGF stimulates vascular
endothelial cells to proliferate (Breier et al., 1992). Since
IL-22 cooperates with IL-17 for Th17 to function as an
immunomodulator in certain conditions (Boniface et al.,
2007; Zheng et al., 2007), the synergistic effects of these two
cytokines were also tested. IL-17 and/or IL-22 was added at
the starting of experimental NHEK culture. Three-day culture
supernatants were measured for the above-mentioned cyto-
kines, chemokines, and VEGF. As compared with the non-
addition control, IL-17 markedly augmented production of
proinflammatory cytokine GM-CSF (Figure 5) and TNF-a
(data not shown), whereas IL-22 enhanced TNF-a but not
GM-CSF. As for chemokines, IL-17 highly increased IL-8
production (Figure 5), but decreased CCL5 that of (data not
shown), and IL-22 virtually shared these effects with IL-17,
but to a lesser extent. CXCL10 production was augmented by
both IL-17 and IL-22, with the latter being stronger, whereas
CCL22 level was not changed by either IL-17 or IL-22 (data
not shown). The production of VEGF was upmodulated by IL-
17 but not IL-22. The results suggest that IL-17 is a powerful
stimulator for keratinocytes to produce skin inflammation-
associated molecules. Synergistic effects of IL-17 and IL-22
were remarkably found on IL-8 production (Figure 5),
whereas they did not exhibit additive or synergistic effects
on the other products.
DISCUSSION
Intracellular detection of IL-17 is necessary for enumeration
of Th17 cells in PBMCs. In this study, we successfully
counted their percentage by flow cytometry and investigated
whether this particular T-cell population was changed in
number in AD patients. Our study demonstrated that Th17
cells were increased in percentage in PBMCs of AD patients
and infiltrated in the eczematous lesions of AD, and IL-17
stimulated keratinocytes to produce cytokines/chemokines
and VEGF. It is noteworthy that percentage of IL-17þCD4þ
cells in AD patients was slightly lower than that of psoriatic
patients, a well-known disease whose pathogenesis involves
Th17 (Zheng et al., 2007).
The important role of Th17 cells for AD is suggested by the
finding that percentage of Th17 was associated with severity
of AD. The percentage of Th17 was significantly correlated
with the percentage of IFN-g-producing Th1 cells, but not
with that of IL-4-producing Th2 cells. Moreover, there was no
strong association of Th17 cells with Th1/Th2 balance. These
results suggest that Th17 cells participate in the development
of AD as an enhancer, but not an immune-polarizer, of AD.
While IFN-g-producing T cells are involved in the chronic
lesions of AD (Grewe et al., 1994), Th17 cells possibly play
a role for prolonged exaggeration of AD lesions.
An immunohistochemical study of atopic eczema re-
vealed infiltration of IL-17-secreting cells in the lesional skin.
In accordance with the previous study (Toda et al., 2003),
Th17 infiltrated more markedly in acute eczematous lesions
than in chronic ones in a severity-dependent manner. Thus,
Th17 is considered to serve as an initial cytokine source for
development of the skin lesions. T-cell-driven keratinocyte
activation plays a relevant role in the pathogenesis of
prolonged inflammatory skin disorders, including AD. Our
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Figure 5. Effects of IL-17 and/or IL-22 on keratinocyte production of
cytokines/chemokines and VEGF. NHEKs were cultured with or without IL-17
and/or IL-22 at the indicated doses. Three-day culture supernatants were
subjected to analysis with the cytometric beads array system or ELISA.
Columns show mean±SD of data using triplicated wells. The asterisk
indicates statistically significant differences compared with the untreated
group (Po0.05, unpaired two-tailed t-test). Data are representative of those
from three independent experiments.
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evaluation of the effects of IL-17 on keratinocyte production
of cytokines, chemokines, and VEGF demonstrated that IL-17
stimulates NHEKs to produce GM-CSF, TNF-a, IL-8, CXCL10,
and VEGF. IL-17 increases production of GM-CSF, IL-6
(Albanesi et al., 2000), and IL-8 (Albanesi et al., 1999)
directly and in synergism with IFN-g, IL-4, and/or TNF-a,
whereas CCL5 production is decreased (Albanesi et al.,
1999). Their observations are virtually the same as ours,
except for CXCL10, which we found to be upregulated by
IL-17 and more remarkable by IL-22. IL-17 also stimulates
keratinocytes to express CD54 in the presence of IFN-g
(Albanesi et al., 1999). Thus, keratinocyte production of
proinflammatory cytokines is augmented in Th17-infiltrating
atopic skin lesions. Th17 also may promote proliferation of
dermal vessels by VEGF, a sequential event for exacerbation
of AD (Wakita et al., 1994).
In previous studies, the synergistic effect of IL-17 and IL-22
has not been studied fully. Since IL-17 and IL-22 are
coexpressed by Th17 cells and expression of both cytokines
is initiated by transforming growth factor-b (Liang et al.,
2006; Zheng et al., 2007), their synergistic effects on
keratinocytes are an issue to be clarified, but has been
reported in only one study, which demonstrated synergism in
keratinocyte expression of antimicrobial peptides (Zheng
et al., 2007). We found significant synergism in IL-8
production, but not for any other products.
Psoriasis and AD are two representative inflammatory skin
diseases. Although mediated by Th1 (Gudjonsson et al.,
2004) and Th2 cells (Leung and Soter, 2001), respectively,
there are exacerbating factors common to these disorders, as
exemplified by keratinocyte-derived proinflammatory cyto-
kines and VEGF (Wakita et al., 1994; Bhushan et al., 1999). It
is suggested that IL-17 is involved in this common process of
skin inflammation as a proinflammatory cytokine.
MATERIALS AND METHODS
All experiments were conducted in accordance with the Declaration
of Helsinki Principles.
Subjects
A total of 23 patients with AD (aged 9–51 years; 13 men and 10
women), and nine healthy non-AD volunteers with low serum IgE
levels (aged 24–38 years; 5 men and 4 women) were enrolled in this
study. AD was diagnosed according to the criteria of Hanifin and
Rajka (1980). Severity of AD was evaluated by the criteria of Rajka
and Langeland (1989) and AD was classified into mild, moderate, or
severe. Serum IgE levels of the patients ranged from 43 to
160,000 IUml1 and averaged 14,149 IUml1. None of the patients
had oral steroids or immunosuppressants. Sixteen patients with
psoriasis vulgaris (aged 26–77 years all men; average PASI score,
11.3þ 2.9) were also tested as a disease control. The study design
was approved by the review board of University of Occupational
and Environmental Health. Measurements in this study were
performed after informed consent had been obtained.
Intracellular cytokine staining of PBMCs
PBMCs were isolated from patients and control subjects by standard
Ficoll–Paque method (Phamacia, Uppsala, Sweden). Intracellular
cytokines were stained according to the protocol of Cytostain
(Immunotech, Marseille, France), with a few modifications. Briefly,
cells (2 106 cellsml1) were incubated in complete RPMI (RPMI-
1640 (Sigma Chemical Co., St Louis, MO) containing 10% heat-
inactivated fetal calf serum (Invitrogen, Carlsbad, CA), 5 105 M
2-mercaptoethanol, 2mM L-glutamine, 25mM HEPES (Cellgro,
Herndon, VA), 1mM non-essential amino acids, 1mM sodium
pyruvate, 100Uml1 penicillin, and 100 mgml1 streptomycin) in
a 24-well plate with 10 ngml1 of phorbol-12-myristate 13-acetate
(Sigma Chemical Co.), 106 M of ionomycin (Wako, Osaka, Japan),
and 0.7 ml of Golgistop (BD Biosciences, San Diego, CA) for
8 hours. Then, cells were washed and directly stained with
PerCP-conjugated anti-CD8 mAb (BD Biosciences) and subse-
quently with APC-conjugated anti-CD3 mAb (BD Biosciences) for
20minutes at 4 1C. After washing, 100ml of Cytofix/Cytoperm buffer
(BD Biosciences) was added to each well and incubated for
20minutes at room temperature, and washed with Perm/Wash
solution as per manufacture’s protocol (BD Biosciences). They were
stained with phycoerythrin-labeled anti-IL-17, IL-4, or IL-5, and
FITC-labeled anti-IFN-g mAb, for 20minutes at 4 1C. Fluorescence
profiles were analyzed by flow cytometry in FACSCanto (BD
Biosciences).
Immunohistochemical staining
We obtained 27 biopsy specimens from 13 atopic patients. The
specimens were obtained from acute and chronic lesions of AD and
frozen in Tissue-Tek OCT compound. Chronic lesions were defined
as lichenified or pruriginous eruptions, and scaly erythematous
lesions were categorized as acute lesions. Cryostat sections (7 mm)
were fixed in acetone and stained as described previously
(Kabashima et al., 2005) with rat anti-human IFN-g, IL-4, and IgG1
(BD Biosciences), and mouse anti-human IL-17 and IgG1 (eBio-
sciences, San Diego, CA). Rat and mouse antibodies were detected
using biotinylated anti-rat and mouse IgG (Dako Cytomation, Kyoto,
Japan), followed by treatment with horseradish peroxidase-conju-
gated streptoavidin (KPL, Gaithersburg, MD). Peroxidase enzyme
reactions were developed with conventional substrates, diamino-
benzidine (Sigma Chemical Co.). The sections were lightly counter-
stained with hematoxylin. The number of immunoreactive
lymphocytes was enumerated from five HPFs in the dermis of each
immunostained section. Data were expressed as the number of IL-17
cells/HPF.
Keratinocyte culture and measurements of cytokines and VEGF
NHEKs were purchased from Cascade Biologics (Portland, OR).
They were grown in the serum-free keratinocyte Epilife growth
medium (Cascade Biologics) and used at the third passage in all
experiments (Kobayashi et al., 2007). Growth supplement was
omitted 48 hours before experiments. IL-17 and/or IL-22 (R&D
Systems, Minneapolis, MN) were added at the beginning of
experimental culture using 24-well plates (Corning Glass Works,
Corning, NY). Three-day culture supernatants were examined for
GM-CSF, TNF-a, IL-8, RANTES/CCL5, IP-10/CXCL10, MDC/CCL22,
and VEGF levels. The concentration of these substances, except for
that of CCL22, was measured using cytometric beads array system
(BD Bioscience) according to the manufacturer’s protocol. The
concentration of CCL22 was measured using ELISA kits (BD
Bioscience) according to the manufacturer’s directions.
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Statistical analysis
Student’s t-test (impaired) was employed to determine statistical
differences between means. Correlations were studied by Pearson
product-moment correlation coefficient.
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